Presentation: The Emerging Science and Clinical Practice of Cardio Oncology

Speaker: Amin F. Rahmatullah, MD
Director, Cardiac CT Program; Director, Heart Failure Program
Metropolitan Heart and Vascular Institute, Mercy and Unity Heart Center

Date: Monday, January 26, 2015, 7:00 – 8:00 AM
Location: ANW Education Building, Watson Room

OBJECTIVES
At the completion of this activity, the participants should be able to:
1. Appreciate the cardiotoxic potential of some newer chemotherapeutic agents to treat common malignancies.
2. Screen and detect early signs of cardiotoxicity of these chemotherapeutic agents
3. Describe intervention to prevent and halt progression of cardiotoxicity of these chemotherapeutic agents

ACCREDITATION
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Allina Health and Minneapolis Heart Institute Foundation. Allina Health is accredited by the ACCME to provide continuing medical education for physicians.

Allina Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: This activity has been designed to meet the Minnesota Board of Nursing continuing education requirements for 1.2 hours of credit. However, the nurse is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Others: Individuals representing other professional disciplines may submit course materials to their respective professional associations for 1.0 hours of continuing education credit.

DISCLOSURE STATEMENTS
Speaker(s): Dr. Rahmatullah has declared that he does not have a conflict of interest in making this presentation.

Planning Committee: Dr. Michael Miedema and Eva Zewdie have declared that they do not have any conflicts of interest associated with the planning of this activity. Dr. Robert Schwartz declared the following relationships - stockholder: Cardiomind, Interface Biologics, Aritech, DSI/Transoma, InstyMeds, Intervale, Medtronic, Osprey Medical, Stout Medical, Tricardia LLC, CoAptus Inc, Augustine Biomedical; scientific advisory board: Abbott Laboratories, Boston Scientific, MEDRAD Inc, Thomas, McNerney & Partners, Cardiomind, Interface Biologics; options: BackBeat Medical, BioHeart, CHF Solutions; speakers bureau: Vital Images; consultant: Edwards LifeSciences.